Eagle Pharmaceuticals, INC.
At a glance
Employees20-99
In business sinceNot reported
HeadquartersWoodcliff Lake, NJ
US patents36
SAM.gov UEIVRQKPMHD3CK7
CAGE code7LL94
Incorporated inDE
LEI549300TN20OLYTJVP152
- medicines
- candidates
- critical care
- new chemical entity
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
36 US patents granted 2009–2025, 13 of them in the five years to SEP 2025, including 1 design patent.
Pharmaceuticals 35
- Fulvestrant formulations and methods of their useUS 12,370,199 · granted JUL 29, 2025
- Fulvestrant formulationsUS 12,350,339 · granted JUL 8, 2025
- Formulations of bendamustineUS 12,350,257 · granted JUL 8, 2025
- Formulations of bendamustineUS 12,343,333 · granted JUL 1, 2025
- Fulvestrant formulations and methods of their useUS 12,186,427 · granted JAN 7, 2025
Newest 5 shown · Granted to Eagle Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Eagle Pharmaceuticals, INC. | Woodcliff Lake | NJ | 20–99 | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.